Management of peripheral levodopa resistance in Parkinson’s disease

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510629-24-00

Enrollment

Registered

2024-12-16

Start date

2025-05-14

Completion date

Unknown

Last updated

2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Brief summary

Proportion of responders (defined as >30.0% decrease in MDS-UPDRS-III compared to pre-treatment), apomorphine versus levodopa, MDS-UPDRS-IIIΔOFF-ONΔposttreatment-pretreatment, rifaximin compared to placebo

Detailed description

MDS-UPDRS IIIΔOFF-ON, Composite Clinical Motor Score (CCMS), Modified Hoehn & Yahr scale, Global Rating of Change (GRC), Modified GIDS-PD

Interventions

DRUGPlacebo capsules

DRUGXIFAXAN 550 mg filmomhulde tabletten

DRUGMadopar 125 mg

DRUGdispergeerbare tabletten

DRUGDacepton 10 mg/ml oplossing voor injectie in een patroon

DRUGDomperidon Accord 10 mg

DRUGtabletten

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportion of responders (defined as >30.0% decrease in MDS-UPDRS-III compared to pre-treatment), apomorphine versus levodopa, MDS-UPDRS-IIIΔOFF-ONΔposttreatment-pretreatment, rifaximin compared to placebo	—

Secondary

Measure	Time frame
MDS-UPDRS IIIΔOFF-ON, Composite Clinical Motor Score (CCMS), Modified Hoehn & Yahr scale, Global Rating of Change (GRC), Modified GIDS-PD	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026